Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal

Core Viewpoint - The deal will enhance the cardiovascular drug pipeline of the Swiss pharmaceutical company [1] Group 1 - The transaction is expected to significantly strengthen the company's position in the cardiovascular market [1]